An observational study of functional abilities in infants, children, and adults with type 1 SMA
- 21 August 2018
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 91 (8), e696-e703
- https://doi.org/10.1212/wnl.0000000000006050
Abstract
Objective To report cross-sectional clinical findings in a large cohort of patients affected by type 1 spinal muscular atrophy. Methods We included 122 patients, of age ranging between 3 months and 22 years, 1 month. More than 70% (85/122) were older than 2 years and 25% (31/122) older than 10 years. Patients were classified according to the severity of phenotype and to the number of SMN2 copies. Results Patients with the more common and the most severe phenotype older than 2 years were, with few exceptions, on noninvasive ventilation and, with increasing age, more often had tracheostomy or >16-hour ventilation and a gastrostomy inserted. In contrast, 25 of the 28 patients with the mildest phenotype older than 2 years had no need for tracheostomy or other ventilatory or nutritional support. In patients older than 2 years, the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders scores were generally lower compared to those found in younger patients and showed distinct levels of functional abilities according to the severity of the phenotype. Similar findings were also observed on the Hammersmith Infant Neurological Examination. Conclusions Our findings confirm that, after the age of 2 years, patients with type 1 spinal muscular atrophy generally survive only if they have gastrostomy and tracheostomy or noninvasive ventilation >16 hours and have low scores on the functional scales. More variability, however, can be expected in those with the mildest phenotype, who achieve head control. These data provide important baseline information at the time treatments are becoming available.Keywords
This publication has 22 references indexed in Scilit:
- Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophyAnnals of Neurology, 2015
- 209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7–9 November 2014, Heemskerk, The NetherlandsNeuromuscular Disorders, 2015
- Observational study of spinal muscular atrophy type I and implications for clinical trialsNeurology, 2014
- Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)Pediatric Physical Therapy, 2011
- The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): Test development and reliabilityNeuromuscular Disorders, 2010
- Medical Considerations of Long-Term Survival of Werdnig–Hoffmann DiseaseAmerican Journal of Physical Medicine & Rehabilitation, 2007
- Long-Term Survival in Werdnig–Hoffmann DiseaseAmerican Journal of Physical Medicine & Rehabilitation, 2007
- Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophyEuropean Journal of Human Genetics, 2003
- Chaos in the classification of SMA: A possible resolutionNeuromuscular Disorders, 1995
- Chaos in classification of the spinal muscular atrophies of childhoodNeuromuscular Disorders, 1991